Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Applied Pharma Research (APR) and Labtec have regained Ondansetron Oral Dispersible Film’s (ODF) marketing and commercialization rights following the termination of the former license agreement with the BioAlliance, a France-based company that develops specialty products and orphan products for the treatment of cancers.
Subscribe to our email newsletter
The companies can now offer marketing and commercialization rights for Ondansetron ODF in Europe and selected Non-European countries, either through global, regional or local license agreements.
Ondansetron ODF is indicated for the prevention and treatment of chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV) in adults as well as children aged equal or above 6 months, and the prevention and treatment of post operative nausea and vomiting (PONV) in adults and children aged equal or above 4 years.
APR and Labtec have developed Ondansetron ODF as an ‘orodispersible film’ form in collaboration with Monosol RX.
The companis claim the Ondansetron ODF formulation with Rapidfilm technology, a proprietary oral drug delivery technology platform, improves patient compliance by reducing swallowing difficulties.
APR CEO Paolo Galfetti said they are now looking for commercial partners in the various countries of continental Europe with the right sale organization and marketing infrastructure able to maximize the product sale potential.